Safety Study of PTP-001 for Treating Knee Osteoarthritis

Inclusion Criteria: * Written consent to participate in the study * Male or female, aged 40 to 80 years * Symptomatic knee OA with Kellgren-Lawrence radiographic classification of 2 or 3 * Non-responsive after at least 3 months of conservative therapy for knee OA * Females of childbearing potential must have negative pregnancy test result prior to treatment and must commit to highly effective methods of contraception for at least 6 months after treatment * Willingness to report oral analgesic treatment used for knee pain and to discontinue analgesic treatment for knee pain in 24 hours prior to each study visit * Willingness to limit use of pain rescue medication to oral acetaminophen for management of painful knee OA flare Exclusion Criteria: * Body mass index (BMI) ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with condition that warrants weight loss surgery * Presence of active infection of index knee or systemic infection requiring treatment within 3 months of Screening * Administration of IA injection within 3 months of Screening * Significant acute injury to index knee within 3 months of Screening * Surgery to index knee within 6 months of Screening or planned surgery to index knee within 6 months after Screening * Unstable index knee joint * History of radiation therapy of index knee * Known vascular or neurological disorder affecting the index knee * Osteonecrosis of either knee * Clinical diagnosis of inflammatory arthritis * Clinical diagnosis of autoimmune disease affecting the musculoskeletal system * Use of any other investigational therapy within 3 months of Screening or planned for the duration of the study * Current anti-coagulant use * History of receiving a solid organ or hematologic transplant * History of malignancy or radiotherapy within 5 years of Screening, except for basal or squamous cell carcinoma of the skin * Use of immunosuppressive or chemotherapeutic agents within 5 years of Screening * Known allergy to local anesthetics or allograft tissues * Known history of hepatitis * Known history of thrombotic or thromboembolic phenomena. * Known history of primary or secondary immunodeficiency disorders * Presence of concurrent medical condition that, in the investigator's judgement, could compromise participant safety or interfere with the required study assessments and study participation. Note: Other protocol defined inclusion/exclusion criteria apply.